Modified Systemic Inflammation Score Is an Independent Predictor of Long-Term Outcome in Patients Undergoing Surgery for Adenocarcinoma of the Esophagogastric Junction

Jianping Xiong, Wenzhe Kang, Fuhai Ma, Hao Liu, Shuai Ma, Yang Li, Peng Jin, Haitao Hu and Yantao Tian*

Department of Pancreatic and Gastric Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Background: The modified systemic inflammation score (mSIS), which is calculated by a composite score of the lymphocyte-to-monocyte ratio and the albumin content in serum, is identified as the new score to predict the prognosis for various cancers. However, its significance for patients with adenocarcinoma of esophagogastric junction (AEJ), who receive surgery, remains unclear.

Methods: This study retrospectively analyzed 317 patients with AEJ receiving surgery between September 2010 and December 2016. The associations between the mSIS and the clinicopathological features, overall survival (OS), as well as relapse-free survival (RFS), were assessed. In addition, the time-dependent receiver operating characteristic (t-ROC) curve analysis was performed for comparing the value of those scoring systems in predicting patient prognosis.

Results: Of the 317 cases, 119 were rated as mSIS 0, 123 as mSIS 1, and 75 as mSIS 2. Besides, mSIS was significantly related to age and tumor size. On multivariate analysis, mSIS was identified as a predictor to independently predict OS ($p < 0.001$) along with RFS ($p < 0.001$), and a significantly strong correlation was observed at the advanced pTNM stages based on the mSIS system. In the subgroup analysis of adjuvant chemotherapy and surgery alone, mSIS was still the predictor for independently predicting patient OS ($p < 0.001$) together with RFS ($p < 0.001$) for the two groups. T-ROC analysis showed that mSIS was more accurate than controlling nutritional status score in predicting OS and RFS.

Conclusions: The mSIS can serve as an easy, useful scoring system to independently predict the preoperative survival for AEJ cases undergoing surgery.

Keywords: adenocarcinoma of the esophagogastric junction, modified systemic inflammation score, albumin, prognostic factors, lymphocyte-to-monocyte ratio
INTRODUCTION

Adenocarcinoma of the esophagogastric junction (AEJ) is defined as the adenocarcinoma at the gastroesophageal junction with an epicenter in a range of 5 cm (1). The incidence of AEJ has increased rapidly over the last few decades, especially in western countries (2). Keeney et al. discovered that the incidence of AEJ increased by 20% in 1998; particularly, it elevated by three to four times in patients aged over 65 years (3). AEJ is an aggressive malignancy with 5-year survival after diagnosis of < 20% (4). The currently recognized prognostic factors for patients with AEJ include tumor stage, vascular invasion, and lymphatic invasion, but these postoperative factors cannot be used routinely, which has severely limited their clinical application. To more efficiently evaluate the risks of disease progression and postoperative death in patients with AEJ, we need to determine and characterize new factors.

Systemic inflammation exerts a vital part in cancer pathogenesis and occurrence; besides, the systemic inflammation markers are related to cancer survival (5, 6). The serum contents of inflammatory biomarkers before treatment, including the platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), as well as neutrophil-to-lymphocyte ratio (NLR), have been recognized to be related to the progression and prognosis of many cancers, like gastric cancer (GC), hepatocellular carcinoma (HCC), and esophageal cancer (EC) (7, 8). In addition, the preoperative serum albumin level has also been used to predict the survival outcomes for lung cancer (LC), GC and EC (9, 10). Recently, Galizia et al. have first reported that a new scoring system according to the LMR and albumin concentration in serum, which was called the modified systemic inflammation score (mSIS) and it might comprehensively reflect nutritional status and systemic inflammation in patients with cancer (11). The mSIS was strongly related to the survival for patients with GC, esophageal squamous cell carcinoma (ESCC), and lymphoma (12–14). Besides, it is suggested that, compared with other prognostic factors, including the modified Glasgow Prognostic Score and the original systemic inflammation score, the mSIS is more accurate in predicting survival (12, 13). Also, it is proposed that AEJ should be considered separately from EC or GC due to its unique clinicopathological characteristics and survival outcome (15). So far, the value of mSIS in predicting the prognosis for patients with AEJ after surgical resection has not been investigated. Therefore, the present retrospective cohort study was carried out at a large center to determine the significance of mSIS in predicting the prognosis for patients with AEJ and to investigate the associations between mSIS and other clinicopathological features.

MATERIALS AND METHODS

Objects of Study

Adenocarcinoma of the esophagogastric junction cases receiving surgery from September 2010 to December 2016 at the Department of Pancreatic and Gastric Surgery in the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College was evaluated in this study in a retrospective manner. The following inclusion criteria were applied: (1) a histologically confirmed adenocarcinoma of the esophagogastric junction; (2) no evidence of tumors invading adjacent organs, paraortic lymph node enlargement, or distant metastasis demonstrated by abdominal computed tomography and/or magnetic resonance imaging (MRI) and posteroanterior chest radiography; and (3) a D1/D1+ D2 lymphadenectomy with a curative R0 resection. Patients conforming to any one of the criteria below were excluded from this study: (1) those receiving palliative surgery, (2) those who did not receive routine preoperative blood test, (3) those with distant metastasis (DM) at the time of surgery, (4) those receiving neoadjuvant chemotherapy (NCT), (5) those with other organ malignancies, (6) those receiving emergency operation, (7) those with other synchronous malignancies, (8) those with incomplete/inaccurate medical records, (9) those with chronic liver and/or kidney diseases, a chronic inflammatory disorder, active infection in any form, hematological diseases and autoimmune diseases, etc., (10) those with missing laboratory data, and (11) those with missing follow-up data. At last, 317 cases were included in the present study (Figure 1). The demographic, laboratory, and histopathological variables from the enrolled cases, together with the extracted data from our hospital database and patient records, were examined retrospectively. The clinical tumor stage was determined in accordance with the Pathological Tumor Lymph Node Metastasis (pTNM) classification (8th edition) released by the International Union for Cancer Control (UICC). Adenocarcinomas with epicenters are more than 2 cm from AEJ and enter the proximal stomach and are staged as stomach cancers; cardia cancer that does not involve AEJ (epicenters are < 2 cm from AEJ) is staged as stomach cancers; adenocarcinomas with epicenters no more than 2 cm into the gastric cardia are staged as esophageal adenocarcinomas. AEJs were classified into three subtypes (Type I, Type II, and Type III) according to Siewert’s classification (16). The appropriate way of surgical procedure was selected according to the location of AEJ ( abdominoothoracic en bloc esophagectomy or transthiatal extended gastrectomy, respectively). The multidisciplinary team of oncology discussed the treatment for each patient before surgery. Oxaliplatin/capecitabine or cisplatin/5-fluorouracil was recommended for the patients with advanced AEJ as the adjuvant chemotherapy.

Definition of Inflammation-Based Indicators

A routine blood test was performed a week before surgery. The results of blood tests conducted a week before surgery were obtained from the laboratory database of the National Cancer Center (Beijing, China). No patient developed the signs of pyrexia (axillary temperature ≥ 37.2°C/99.9°F), a chronic inflammatory disorder, or active infection in any form. Preoperative data, including body mass index (BMI), serum albumin concentration, tumor size, American Society of Anesthesiologists (ASA) score, total cholesterol level, and the absolute neutrophil/monocyte/lymphocyte counts, were collected. By using the method reported by Lin et al., mSIS was
calculated by serum albumin content and LMR. For cases who had serum albumin concentration < 40 g/l and LMR < 3.4, the score was 2; for those having either serum albumin content ≥ 40 g/l or LMR ≥ 3.4, the score was 1; and for those having the serum albumin content ≥ 40 g/l and/or LMR ≥ 3.4, the score was 0 (Supplementary Table 1). The controlling nutritional status

FIGURE 1 | (A) Kaplan–Meier curves of OS for each mSIS group. (B) Kaplan–Meier curves of RFS for each mSIS group. (C) Association of the mSIS with the OS in the adjuvant chemotherapy group. (D) Association of the mSIS with the OS in the surgery-alone group. (E) Association of the mSIS with the RFS in the adjuvant chemotherapy group. (F) Association of the mSIS with the RFS in the surgery-alone group. OS, overall survival; RFS, relapse-free survival; AEG, adenocarcinoma of the gastroesophageal junction; mSIS, modified systemic inflammation score.
(CONUT) score was calculated according to the preoperative serum albumin level, total cholesterol content, and peripheral lymphocyte count (17) by the method reported previously (4) (Supplementary Table 2). MaxStat analysis was carried out to determine the optimal CONUT threshold. Patients were classified into high (≥3) and low (≤2) CONUT score groups.

Follows-Up
Patients were followed up after surgery at intervals of 3 months within the first 2 years and intervals of 6 months thereafter. The last follow-up assessment was carried out in October 2019. The follow-up examinations included abdominopelvic CT, chest X-ray, tumor markers (including CEA, CA19-9, and CA72-4), and annual endoscopy. Overall survival (OS) was deemed as the primary endpoint, which indicated the duration between surgery and death. Death from any cause was considered as an event.

Statistical Methods
Categorical data were analyzed by chi-square test, while continuous data were analyzed by t-tests. Kaplan–Meier survival curve was plotted, and differences between the curves were analyzed using the log-rank test. Variables with \( p < 0.05 \) were identified based on univariate analysis, which was then incorporated into the Cox regression model for multivariate analysis. In addition, the time-dependent receiver operating characteristic (t-ROC) curves were plotted, while area under the curve (AUC) values were adopted for comparing mSIS and CONUT for their prognostic predicting performance (18). Each test was bilateral, and a difference of \( p < 0.05 \) was considered statistically significant. Rver.4.0.2 (R Foundation for Statistical Computing, Vienna, Austria) and SPSS18.0 (SPSS Inc, Chicago, IL, USA) were used for statistical analysis. Moreover, the “rms” function of the R package was used to calculate C-index values, while the “timeROC” function of the R package was employed for t-ROC analysis. The present study gained approval from the Ethics Review Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College.

RESULTS

Patient Characteristics
Totally, 317 AEJ cases were enrolled into the present study (Supplementary Figure 1). There were 265 (83.6%) male and 52 (16.7%) female patients. For all patients, their age at surgery ranged from 36 to 86 (average, 58.2) years. According to the pTNM classification system, there were 63 (19.9%) stage I patients, 93 (29.3%) stage II patients, and 161 (50.8%) stage III patients. Fifteen had type I (4.8%) AEJs, 190 had type II (59.9%), and 112 had type III (35.2%). Among the 317 patients, 165 (52%) underwent adjuvant chemotherapy. In line with the mSIS system, 119 patients (37.5%) were divided into the mSIS = 0 group, 123 (38.8%) were in the mSIS = 1 group, and 75 (23.7%) were in the mSIS = 2 groups (Table 1).

Relationships of the Preoperative mSIS System With Clinicopathological Features
Table 1 presents the relationships of the mSIS system with clinicopathological features. As observed from the table, the mSIS was significantly related to age and tumor size. However, there was no difference in BMI, ASA score, tumor differentiation, perineural invasion, vascular involvement, pTNM stage, surgical approach, or adjuvant chemotherapy among the three mSIS groups. Moreover, mSIS increased among cases who had serum albumin (mg/dL) < 40 and LMR ≤ 3.40.

OS and RFS Based on MSIS
The OS and RFS curves were statistically analyzed, as depicted in Figure 1. The OS rates at 1, 3, and 5 years of the included cases were 87.6, 62.8, and 44.7%, respectively. The median OS and RFS of all included patients were 49.3 and 40.7 months, respectively. For the mSIS groups, the median OS of the mSIS = 0, 1, and 2 groups were 60.2, 48.3, and 33.7 months, respectively. Additionally, the median RFS of the mSIS = 0, 1, and 2 groups were 48.1, 40.4, and 29.3 months, respectively. The Kaplan–Meier survival analysis indicated that the high mSIS was related to the poor OS and RFS for all the included patients (Figures 1A,B). Furthermore, the survival differed significantly based on the mSIS in the surgery-alone group and the postoperative adjuvant chemotherapy group (Figures 1C–F). Moreover, after stratification according to the pTNM stage, the stage III subgroup showed the most significant differences in OS and RFS based on the mSIS system (Figure 2).

Univariate and Multivariate Analysis on the Predictors for AEJ Patient Prognosis
On the one hand, univariate analysis found that tumor size (HR = 1.17, \( p < 0.001 \)), tumor differentiation (G2: HR = 1.40, \( P = 0.009 \); G3: HR = 1.98, \( P = 0.004 \)), pTNM stage (II:HR = 2.48, \( P = 0.002 \); III: HR = 6.10, \( P = 0.001 \)), perineural invasion (HR = 2.02, \( P = 0.010 \)), lymphatic invasion (HR = 2.63, \( P = 0.017 \)), and vascular invasion (HR = 1.65, \( p < 0.001 \)) were associated with OS (Table 2). In multivariate analyses, pTNM stage, vascular invasion, lymphatic invasion, and CONUT scores were the factors that independently predicted OS (Table 2; Supplementary Figure 2). On the other hand, univariate analysis determined that tumor differentiation, tumor size, pTNM stage, vascular invasion, lymphatic invasion, perineural invasion, and CONUT scores were the important prognostic factors (Table 3). Results of multivariate analysis suggested that perineural invasion (HR = 1.90, \( p < 0.001 \)), vascular invasion (HR = 1.76, \( p < 0.001 \)), and pTNM stage (II:HR = 1.80, \( p < 0.001 \); III: HR = 4.89, \( p < 0.001 \)), together with CONUT scores (HR = 1.86, \( p < 0.001 \)), were the factors to independently predict RFS (Table 3; Supplementary Figure 3). And we have analyzed the data stratified by the subgroup of AEJ (Supplementary Tables 3, 4).

Prognostic Value of mSIS
Time-dependent receiver operating characteristic curve was plotted to compare the prognostic values of mSIS and CONUT (Figure 3). During the whole observation period, the t-ROC
TABLE 1  | Association of mSIS and clinicopathological characteristics in patients with AEJ.

| Clinicopathological features          | All cases | mSIS0 (n = 119) | mSIS1 (n = 123) | mSIS2 (n = 75) | P value |
|--------------------------------------|-----------|-----------------|-----------------|----------------|---------|
| Age (median)                         | 63.4      | 59.5            | 63.9            | 68.4           | 0.003   |
| Gender                               |           |                 |                 |                |         |
| Male                                 | 265 (83.6)| 94 (79.0)       | 106 (85.4)      | 66 (87.0)      | 0.112   |
| Female                               | 52 (16.4) | 25 (21.0)       | 18 (14.6)       | 9 (12.0)       |         |
| BMI (median)                         | 23.8      | 24.5            | 23.2            | 23.6           | 0.601   |
| ASA score                            |           |                 |                 |                |         |
| 1                                    | 23 (7.3)  | 9 (7.5)         | 11 (8.9)        | 3 (4.0)        | 0.425   |
| 2                                    | 243 (76.7)| 93 (78.2)       | 87 (70.8)       | 63 (84.0)      |         |
| 3                                    | 51 (16.0) | 17 (14.3)       | 25 (20.3)       | 9 (12.0)       |         |
| Tumor size (cm, median)              | 4.8       | 4.2             | 4.7             | 6.0            | 0.008   |
| Vascular invasion                    |           |                 |                 |                |         |
| Negative                             | 197 (62.1)| 81 (68.1)       | 75 (61.0)       | 39 (52.0)      | 0.366   |
| Positive                             | 120 (37.9)| 38 (31.9)       | 48 (39.0)       | 36 (48.0)      |         |
| Perineural invasion                  |           |                 |                 |                |         |
| Negative                             | 146 (66.1)| 53 (44.6)       | 59 (48.0)       | 34 (45.3)      | 0.710   |
| Positive                             | 171 (53.9)| 66 (55.4)       | 64 (52.0)       | 41 (54.7)      |         |
| Lymphatic invasion                   |           |                 |                 |                |         |
| Negative                             | 170 (53.7)| 70 (58.5)       | 63 (51.2)       | 37 (49.3)      | 0.509   |
| Positive                             | 147 (46.3)| 49 (41.5)       | 60 (48.8)       | 36 (50.7)      |         |
| Surgical approach                    |           |                 |                 |                |         |
| Abdominal                            | 83 (24.2) | 26 (21.8)       | 45 (35.8)       | 12 (17.3)      | 0.416   |
| Thoracoabdominal                     | 234 (73.8)| 93 (78.2)       | 78 (64.2)       | 63 (82.7)      |         |
| pTNM stage                           |           |                 |                 |                |         |
| I                                    | 63 (19.8) | 27 (22.7)       | 21 (17.1)       | 15 (20.0)      | 0.283   |
| II                                   | 93 (29.3) | 39 (32.8)       | 43 (35.9)       | 11 (14.7)      |         |
| III                                  | 161 (50.8)| 53 (44.5)       | 59 (48.0)       | 49 (65.3)      |         |
| Adjuvant chemotherapy                |           |                 |                 |                |         |
| No                                   | 152 (47.9)| 57 (47.3)       | 64 (52.1)       | 31 (41.3)      | 0.609   |
| Yes                                  | 165 (52.1)| 62 (52.1)       | 59 (47.9)       | 44 (58.7)      |         |
| Serum albumin (g/L)                  |           |                 |                 |                | < 0.001 |
| ≥40                                  | 180 (56.8)| 115 (96.6)      | 65 (52.8)       | 0              |         |
| <40                                  | 137 (43.2)| 4 (3.4)         | 58 (48.2)       | 75 (100)       |         |
| Lymphocyte: monocyte ratio           |           |                 |                 |                | < 0.001 |
| ≥3.4                                 | 207 (65.3)| 114 (97.8)      | 93 (75.6)       | 0              |         |
| <3.4                                 | 110 (34.9)| 5 (4.2)         | 30 (24.4)       | 75 (100)       |         |

mSIS, modified systemic inflammation score; AEJ, adenocarcinoma of the gastroesophageal junction; BMI, body mass index; ASA, American Society of Anesthesiologists.

curve for mSIS still outperformed that for CONUT. Furthermore, when evaluating the predicting performance of mSIS and CONUT for OS, at 3 and 5 years postoperatively, the values of AUC for CONUT remarkably decreased compared with those for mSIS (3-year: 0.658 vs. 0.709, \( P = 0.010 \); 5 years: 0.616 vs. 0.701, \( P < 0.001 \)). Also, the mSIS showed significantly higher accuracy than CONUT in predicting the 5-year RFS (5 years: 0.695 vs. 0.620, \( P < 0.001 \)). In addition, the time-dependent receiver operating characteristic (t-ROC) curves and the predicted values of area under the curve (AUC) were also used to compare the prognostic value of mSIS, ALB, and LMR. As suggested by the results of t-ROC curve analysis to predict OS by different scoring systems, the AUC value was high for mSIS compared with those for other scoring systems. Typically, the AUC values in the prediction of 5-year OS were 0.695, 0.519, and 0.491 for mSIS, ALB, and LMR, respectively.

**DISCUSSION**

The present study had first assessed the associations between preoperative mSIS, clinicopathological factors, and survival, and...
investigated the significance of mSIS in predicting prognosis for AEJ cases who received surgery. The results indicated that mSIS was strongly associated with age and tumor size. The higher mSIS showed a tight correlation with the shorter survival, as indicated by univariate analysis. More importantly, mSIS was recognized to be a factor that independently predicted
survival, and an especially strong correlation was observed at advanced pTNM stages. Besides, t-ROC curves were plotted for comparing mSIS and CONUT for their prognosis-predicting performance. Our study showed that mSIS tended to be superior to CONUT in predicting the 3- and 5-year OS along with the 5-year RFS.

Since Virchow first systematically reported the relationship of inflammation with cancer in the 19th century, an increasing number of studies have shown that systemic inflammation is an important part of the tumor microenvironment (TME) \cite{5, 19}. Accumulating...
evidence indicates that the inflammatory reaction in the microenvironment contributes to tumor progression, including the induction of angiogenesis, tumor cell proliferation, and metastasis (20). As identified by accumulating studies, the inflammation-related prognosis scoring systems, including NLR, PLR, or LMR, are related to cancer prognoses, like GC, HCC, or ESCC (21, 22). However, the situation of the host can affect the prognostic abilities of a single inflammation-related marker, whereas a single marker may even be misleading when the cutoff value is arbitrarily determined. Recently, many studies have reported that mSIS, which is determined according to the LMR and serum albumin concentration before surgery, is the new inflammation-related prognosis scoring system. Researchers have identified that mSIS is of prognostic value for GC, lymphoma, and ESCC (12–14). It takes into account the effects of systemic inflammation together with the nutritional status on cancer prognosis. As a result, mSIS outperforms other single inflammatory or nutritional markers. As suggested by the results of t-ROC curve analysis to predict OS by different scoring systems, the AUC value was high for mSIS compared with those for ALB and LMR. Thus, mSIS was more accurate than its single components (ALB and LMR) in predicting OS.

Growing studies have determined the relationships of systemic inflammation and malnutrition with tumorigenesis, growth, metastasis, and progression. This has been confirmed in various cancers, including GC and EC; as a result, more efforts have been devoted to looking for the inflammation- and nutrition-related markers and developing a novel prognostic scoring system. In particular, the reduced albumin content in serum can serve as a sign of malnutrition and systemic inflammation. Tserum albumin content may be reduced by pro-inflammatory factors, including interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-a), which directly inhibit hepatocyte albumin production (23, 24). The serum albumin concentration is currently included in most scoring systems. Hyperproteinemia is related to the better survival of AEJ, consistent with our results. LMR is linked with the numbers of monocytes and lymphocytes. Of them, lymphocytes are the fundamental unit in the innate and adaptive immune systems, which also lay the cell foundation for immune surveillance as well as immune editing (25). Lymphocytes can enhance the cancer immune surveillance ability, thereby inhibiting the proliferation, invasion, and metastasis of tumor cells (25). It is indicated that tumor-infiltrating lymphocytes are associated with the improved prognosis for various cancers, which may be attributed to the anti-tumor activity and angiogenesis inhibition induced by tumor-infiltrating lymphocytes (26). Therefore, lymphopenia is associated with a poor prognosis for patients with cancer. Previous studies have reported that the monocytes in circulation possibly facilitate cancer growth while decreasing immune monitoring (27). In addition, studies have shown that monocytes may promote the metastasis of tumor cells through tumor-monocyte-endothelial interaction (28). The increased number of neutrophils around the tumor may inhibit cytotoxic CD8 T cells for their anti-tumor activity, resulting in tumor growth and metastasis (29). Therefore, the increased number of monocytes predicts the poor prognosis for cancer patients, which indirectly indicates the relationship between low LMR and poor prognosis. Consistent with previous studies, LMR was found to exert a vital part in AEJ prognosis in this study. Additionally, as revealed by multivariate analysis, LMR might independently predict OS and RFS.

The CONUT score, which is determined according to the preoperative albumin level in serum, total cholesterol level, and peripheral lymphocyte count, is related to cancer survival and has been proved as the robust inflammatory-related score (17, 30, and 31). It is also considered a useful prognostic indicator for the long-term outcomes of GC and ESCC (30, 31). As
suggested by the results of our study, CONUT was associated with AEJ prognosis, which was found to independently predict OS and RFS. Besides, this study compared the prognostic values of mSIS with CONUT. The t-ROC curve analysis using mSIS and CONUT was performed to predict OS and RFS, which indicated a trend that mSIS had higher AUC than CONUT, indicating that mSIS showed remarkably higher accuracy than SIS in predicting patient survival.

Compared with the existing tools that target immunonutritional interventions, our system had the major strength that, by combining oncological, nutritional, and immunological parameters, it outperformed the existing nutritional indices for predicting the survival outcome, and it targeted the immunonutritional intervention for candidate patients who might benefit the most. The results of our study indicated that early inflammation control and nutritional support might improve the prognosis for patients with cancer. Additionally, mSIS can be identified preoperatively; therefore, it can be used to facilitate decision-making for treatment before surgery and better estimate the survival outcome after surgery. Preoperative identification of patient status could have several uses in clinical practice, including prognostic stratification and treatment. Early detection and improvement of malnutrition and inflammation may result in better patient outcomes (32). Currently, we are investigating this tool in our patients with AEJ to preoperatively improve immune status in patients who have an mSIS score of 1 or 2. In addition, the use of anti-inflammatory agents, such as aspirin or other non-steroidal anti-inflammatory drugs, has been shown to attenuate systemic inflammation and cachexia, improve the postoperative course, and ameliorate tolerance of anticancer therapy and long-term outcome (32–34). Preoperative mSIS is a simple, easily obtainable scoring system strongly associated with an outcome in patients with AEJ who are undergoing surgery. Meanwhile, patients with an elevated preoperative mSIS should be considered at high risk of tumor relapse and considered for tailored therapy. Indeed, our multidisciplinary team is now considering administering adjuvant chemotherapy to patients with early AEJ and a high mSIS, who are undergoing potentially curative surgery. Additional studies will determine whether this strategy will turn out to be rewarding.

Certain limitations should be noted in this study. The main limitation of this study is its lack of neoadjuvanted patients and retrospective design. First, although our study strictly complied with the inclusion and exclusion criteria, there was still selection bias due to its retrospective nature. In addition, patients were included from just one institution, and the cohort was ethnically homogeneous. Second, patients who received neoadjuvant were excluded in order to avoid substantial variations in peripheral blood components induced from the anticancer therapies before surgery, which might lead to confounding bias risks that complicate the actual impact of NPS on postoperative survival. Despite that patients who received neoadjuvant therapy were excluded strictly, we were not sure whether each case was under identical status prior to blood sample collection. Besides, our findings did not apply to AEJ cases receiving neoadjuvant therapy.

CONCLUSIONS

According to results in the present study, preoperative mSIS can serve as a simple and useful predictor to predict AEJ prognosis. Furthermore, it may be adopted to be one part of preoperative prognosis classification and postoperative follow-up for developing an individual treatment for AEJ cases.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Review Committee of National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

JX conceived the study and wrote the manuscript. WK, FM, and HH searched the database, reviewed the studies, and collected the data. HL and SM performed the statistical analyses. YL and PJ performed revision of the manuscript. YT arranged for and provided the funding for this study. All the authors reviewed the manuscript and participated in its revision. YT is the guarantor for this study. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by grants from the National Natural Science Foundation of China (81772642), the Beijing Municipal Science & Technology Commission (Z161100000116045), and Capital’s Funds for Health Improvement and Research (CFH 2018-2-4022). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

ACKNOWLEDGMENTS

We thank to Zhisong Liu for his help in the statistical analyses of our manuscript data.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fsurg.2021.622821/full#supplementary-material

Supplementary Figure 1 | A flow diagram of the cases analyzed. AEG, adenocarcinoma of the gastroesophageal junction.
Supplementary Figure 2 | A, overall survival curves according to the preoperative ALB, B, relapse-free survival curves according to the preoperative ALB, C, overall survival curves according to the preoperative LMR, D, relapse-free survival curves according to the preoperative LMR, ALB, albumin; LMR, lymphocyte-to-monocyte ratio.

Supplementary Figure 3 | A Kaplan-Maier curves of overall survival in the CONUT-high (≥ 3) and CONUT-low (≤ 2) score groups. B, Kaplan-Maier curves of relapse-free survival in the CONUT-high (≥ 3) and CONUT-low (≤ 2) score groups. CONUT, controlling nutritional status.

Supplementary Table 1 | The definition of modified mSIS. mSIS, modified systemic inflammation score; ALB, albumin; LMR, lymphocyte-to-monocyte ratio.

REFERENCES

1. Chevallay M, Bollschweiler E, Chandramohan SM, Schmidt T, Koch O, Demanzoni G, et al. Cancer of the gastroesophageal junction: a diagnosis, classification, management review. Ann N Y Acad Sci. (2018) 1434:132–8. doi: 10.1111/nyas.13954
2. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt P. Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol. (2000) 29:645–54. doi: 10.1093/ije/29.4.645
3. Keeney S, Bauer L T. Epidemiology of adenocarcinoma of the esophagogastric junction. Surg Oncol Clin N Am. (2006) 15:687–96. doi: 10.1016/j.soc.2006.07.014
4. Jomrich G, Paireder M, Kristo L, Baier A, Ilhan-Mutlu A, Preusser M, Asari R, Schoppmann F S. High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma. Ann Surg. (2019) 273:532–41. doi: 10.1097/SLA.000000000003370
5. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. (2004) 434:436–44. doi: 10.1038/nature03705
6. Yang L, Karin M. Roles of tumor suppressors in regulating tumor-associated inflammation. Cell Death Differ. (2014) 21:1677–86. doi: 10.1038/cdd.2014.131
7. Kim EY, Lee JW, Yoo HM, Park CH, Song Y K. The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in gastric cancer? Ann Surg Oncol. (2015) 22:4363–70. doi: 10.1245/s10434-015-4518-5
8. Yodying H, Matsuda A, Miyashita M, Matsumoto S, Sakurazawa N, Yamada M, et al. Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol. (2016) 23:646–54. doi: 10.1245/s10434-015-4869-5
9. Espinosa E, Felu J, Zamora P, González Barón M, Sánchez JJ, Ordónez A, and Espinosa J. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer. (1995) 12:67–76. doi: 10.1016/0169-5002(95)00407-R
10. Matsuda S, Takeuchi H, Kawabuko H, Fukuda K, Nakamura R, Takahashi T, et al. Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transhiatal esophagectomy: comparison with the Glasgow Prognostic Score. Ann Surg Oncol. (2015) 22:302–10. doi: 10.1245/s10434-014-3857-5
11. Galizia G, Lieto E, Auricchio A, Cardella F, Mahlia A, Podzemny V, et al. Naples prognostic score, based on nutritional and inflammatory status, is an independent predictor of long-term outcome in patients undergoing surgery for colorectal cancer. Dis Colon Rectum. (2017) 60:1273–84. doi: 10.1097/DCR.0000000000000961
12. Kanda M, Koike M, Tanaka C, Kobayashi D, Hattori N, Hayashi M, et al. Modified systemic inflammation score is useful for risk stratification after radical resection of squamous cell carcinoma of the esophagus. Ann Surg Oncol. (2019) 26:4773–81. doi: 10.1245/s10434-019-07914-7
13. Lin JX, Lin JP, Xie JW, Wang JB, Lu J, Chen QY, et al. Prognostic importance of the preoperative modified systemic inflammation score for patients with gastric cancer. Gastric Cancer. (2019) 22:402–13. doi: 10.1007/s10120-018-0854-6
14. Huang H, Chen LM, Fang XJ, Guo CC, Lin XP, Hong HM, et al. Prognostic value of the modified systemic Inflammation score in patients with extranodal natural killer/T-cell lymphoma. Front Pharmacol. (2020) 11:593392. doi: 10.3389/fphar.2020.593392
15. Ohno S, Tomisaki S, Oiwa H, Sakaguchi Y, Ichiyoshi Y, Maehara Y, et al. Clinicopathologic characteristics and outcome of adenocarcinoma of the human gastric cardia in comparison with carcinoma of other regions of the stomach. J Am Coll Surg. (1995) 180:577–82.
16. Steurert JR, Stein J H. Classification of adenocarcinoma of the esophagogastric junction. Br J Surg. (1998) 85:1457–9. doi: 10.1046/j.1365-2168.1998.00940.x
17. Ignacio de Ulíbarri J., González-Madroño A., de Villar NG, González P, González B, Mancha A, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. (2005) 20:38–45.
18. Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. (2017) 17:53. doi: 10.1186/s12874-017-0332-6
19. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. (2009) 30:1073–81. doi: 10.1093/carcin/bgp127
20. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. (2006) 441:431–6. doi: 10.1038/nature04870
21. Miyamoto R, Inagawa S, Sano N, Tadano S, Adachi S, Yamamoto M. The Neutrophil-To-Lymphocyte Ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients. Eur J Surg Oncol. (2018) 44:607–12. doi: 10.1016/j.ejso.2018.02.003
22. Zhang H, Shang X, Ren P, Gong L, Ahmed A, Ma Z, et al. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma. J Cell Physiol. (2019) 234:1794–802. doi: 10.1002/jcp.27052
23. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecotits-Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis. (2006) 47:139–48. doi: 10.1053/j.ajkd.2005.09.014
24. Dahn MS, Hsu CJ, Lange MP, Jefferson S L. Effects of tumor necrosis factor-alpha on glucose and albumin production in primary cultures of rat hepatocytes. Metabolism. (1994) 43:476–80. doi: 10.1016/0026-0495(94)90080-9
25. Dunn GP, Old L J, Schreiber D R. The immunobiology of cancer immunosurveillance and immunoeediting. Immunity. (2004) 21:137–48. doi: 10.1016/j.immuni.2004.07.017
26. Azimi F, Scoller RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. (2012) 30:2678–83. doi: 10.1200/JCO.2011.37.8539
27. Augier S, Ciucci T, Luci C, Carle GF, Blin-Wakkach C, Wakkach A. Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host immunosurveillance. *J Immunol.* (2010) 185:7165–73. doi: 10.4049/jimmunol.0902583

28. Evani SJ, Prabhu RG, Gnanaruban V, Finol EA, Ramasubramanian K A. Monocytes mediate metastatic breast tumor cell adhesion to endothelium under flow. *FASEB J.* (2013) 27:3017–29. doi: 10.1096/fj.12-24824

29. Liang W, Ferrara N. The complex role of neutrophils in tumor angiogenesis and metastasis. *Cancer Immunol Res.* (2016) 4:83–91. doi: 10.1158/2326-6066.CIR-15-0313

30. Hirahara N, Tajima Y, Fujii Y, Kaji S, Kawabata Y, Hyakudomi R, et al. Controlling Nutritional Status (CONUT) as a prognostic immunonutritional biomarker for gastric cancer after curative gastrectomy: a propensity score-matched analysis. *Surg Endosc.* (2019) 33:4143–52. doi: 10.1007/s00464-019-06723-2

31. Toyokawa T, Kubo N, Tamura T, Sakurai K, Amano R, Tanaka H, et al. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. *BMC Cancer.* (2016) 16:722. doi: 10.1186/s12885-016-2696-0

32. Tokunaga R, Sakamoto Y, Nakagawa S, Ohuchi M, Izumi D, Kosumi K, et al. A novel independent predictive score for colorectal cancer patients undergoing potentially curative resection. *Int J Colorectal Dis.* (2017) 32:99–106. doi: 10.1007/s00384-016-2668-5

33. Lönnroth C, Andersson M, Asting AG, Nordgren S. and K. Lundholm: Preoperative low dose NSAID treatment influences the genes for stemness, growth, invasion and metastasis in colorectal cancer. *Int J Oncol.* (2014) 45:2208–20. doi: 10.3892/ijo.2014.2686

34. Douglas E, McMillan C D. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. *Cancer Treat Rev.* (2014) 40:685–91. doi: 10.1016/j.ctrv.2013.11.007

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2021 Xiong, Kang, Ma, Liu, Ma, Li, Jin, Hu and Tian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*